ES2716923T3 - Vacuna peptídica que comprende péptido ras mutante y agente quimioterapéutico - Google Patents

Vacuna peptídica que comprende péptido ras mutante y agente quimioterapéutico Download PDF

Info

Publication number
ES2716923T3
ES2716923T3 ES15720986T ES15720986T ES2716923T3 ES 2716923 T3 ES2716923 T3 ES 2716923T3 ES 15720986 T ES15720986 T ES 15720986T ES 15720986 T ES15720986 T ES 15720986T ES 2716923 T3 ES2716923 T3 ES 2716923T3
Authority
ES
Spain
Prior art keywords
peptide
seq
substitution
sequence represented
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15720986T
Other languages
English (en)
Spanish (es)
Inventor
Jon Amund Eriksen
Gustav Gaudernack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Circio Holding ASA
Original Assignee
Targovax ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50679896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2716923(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targovax ASA filed Critical Targovax ASA
Application granted granted Critical
Publication of ES2716923T3 publication Critical patent/ES2716923T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES15720986T 2014-05-06 2015-05-05 Vacuna peptídica que comprende péptido ras mutante y agente quimioterapéutico Active ES2716923T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14167265 2014-05-06
PCT/EP2015/059861 WO2015169804A1 (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
ES2716923T3 true ES2716923T3 (es) 2019-06-18

Family

ID=50679896

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15720986T Active ES2716923T3 (es) 2014-05-06 2015-05-05 Vacuna peptídica que comprende péptido ras mutante y agente quimioterapéutico

Country Status (16)

Country Link
US (1) US9757439B2 (enExample)
EP (1) EP3140320B1 (enExample)
JP (2) JP2017514847A (enExample)
KR (1) KR20170002563A (enExample)
CN (1) CN106414493A (enExample)
AU (1) AU2015257774B2 (enExample)
BR (1) BR112016025764A2 (enExample)
CA (1) CA2947963A1 (enExample)
CL (1) CL2016002794A1 (enExample)
DK (1) DK3140320T3 (enExample)
ES (1) ES2716923T3 (enExample)
IL (1) IL248671B (enExample)
MX (1) MX2016014414A (enExample)
RU (1) RU2700929C2 (enExample)
SG (2) SG11201608712PA (enExample)
WO (1) WO2015169804A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775892B2 (en) 2013-12-09 2017-10-03 Targovax Asa Peptide mixture
RU2765874C2 (ru) 2016-10-26 2022-02-04 МОДЕРНАТиЭкс, ИНК. Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
EP3576780A1 (en) * 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN110709094A (zh) 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 Kras肽疫苗组合物及其使用方法
CA3103983A1 (en) 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN109550044B (zh) * 2018-10-19 2022-05-03 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
CA3141084A1 (en) * 2019-06-12 2020-12-17 Vikram JUNEJA Neoantigen compositions and uses thereof
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
JP2023535981A (ja) * 2020-07-29 2023-08-22 スクイーズ バイオテクノロジーズ カンパニー 有核細胞を使用して変異型Ｒａｓに対する免疫応答を刺激する方法
CN116322752A (zh) * 2020-07-29 2023-06-23 Sqz生物技术公司 使用无核细胞刺激对突变体ras的免疫应答的方法
JP2023550515A (ja) * 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体
EP4423256A2 (en) * 2021-10-28 2024-09-04 Genentech, Inc. Systems and methods to identify mhc-associated antigens for therapeutic intervention
EP4522192A2 (en) * 2022-05-12 2025-03-19 The Johns Hopkins University Neoantigen vaccines for cancer prevention
WO2025103205A1 (en) * 2023-11-15 2025-05-22 Ck Life Sciences Development Limited Pharmaceutical compositions and methods for preventing or treating kras-associated diseases or conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
AU2003301021C1 (en) 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US9775892B2 (en) 2013-12-09 2017-10-03 Targovax Asa Peptide mixture

Also Published As

Publication number Publication date
BR112016025764A2 (pt) 2018-01-16
JP2020100650A (ja) 2020-07-02
RU2016147527A3 (enExample) 2019-01-21
RU2700929C2 (ru) 2019-09-24
SG11201608712PA (en) 2016-11-29
JP7304629B2 (ja) 2023-07-07
CN106414493A (zh) 2017-02-15
EP3140320B1 (en) 2018-12-26
CL2016002794A1 (es) 2017-06-09
MX2016014414A (es) 2017-02-23
AU2015257774A1 (en) 2016-12-22
WO2015169804A1 (en) 2015-11-12
IL248671A0 (en) 2017-01-31
IL248671B (en) 2021-08-31
JP2017514847A (ja) 2017-06-08
EP3140320A1 (en) 2017-03-15
US20170065694A1 (en) 2017-03-09
RU2016147527A (ru) 2018-06-08
US9757439B2 (en) 2017-09-12
DK3140320T3 (en) 2019-04-15
AU2015257774B2 (en) 2018-12-20
KR20170002563A (ko) 2017-01-06
SG10201809701TA (en) 2018-12-28
CA2947963A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
ES2716923T3 (es) Vacuna peptídica que comprende péptido ras mutante y agente quimioterapéutico
ES2541863T3 (es) Vacunas peptídicas para cánceres que expresan antígenos asociados a tumores
ES2751092T3 (es) Polipéptidos
ES2759910T3 (es) Composición y vacuna para el tratamiento del cáncer de pulmón
ES2979072T3 (es) Péptidos largos sintéticos (SLP) para la vacunación terapéutica contra la infección por el virus de la hepatitis B
KR20180129899A (ko) 신생항원 및 이것의 사용 방법
ES2730976T3 (es) Preparaciones combinadas para el tratamiento del cáncer
PT2113253E (pt) Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
US9539299B2 (en) Combination therapy with WT1 peptide vaccine and temozolomide
KR20220143812A (ko) B형 간염 바이러스와 관련된 질병의 치료
US20190241660A1 (en) Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
Zhang et al. Recombinant cell-penetrating trichosanthin synergizes anti-PD-1 therapy in colorectal tumor
Dong et al. Biomimetic nanomedicine cocktail enables selective cell targeting to enhance ovarian Cancer chemo-and immunotherapy
ES2631952T3 (es) Péptidos CDC45L y vacunas que incluyen los mismos
US20230173046A1 (en) Multicomponent chemical composition of a peptide-based neoantigen vaccine
JP5692933B2 (ja) 免疫刺激ＨＩＶＴａｔ誘導体ポリペプチドによる腫瘍治療
ES2739543T3 (es) Péptido de terminal C de acetilcolinesterasa cíclico en el tratamiento o prevención de cáncer o metástasis
ES2742856T3 (es) Composiciones farmacéuticas y procedimientos para el tratamiento y prevención del cáncer metastático
EP4378473A1 (en) Her2 vaccine composition
Jin et al. Application of dsRNA in cancer immunotherapy: Current status and future trends
BR112020010656A2 (pt) tratamento aprimorado de câncer
HK1231899B (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
HK1231899A1 (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
Bravo-Martínez et al. Dendritic cells in the treatment of HIV, cancer and systemic lupus erythematosus
Huang et al. Current advances in the management of atypical teratoid rhabdoid tumors (ATRT)